|Articles|November 15, 2002
- BioPharm International-11-01-2002
- Volume 15
- Issue 11
Inside Washington: Major Changes Ahead for FDA
Author(s)Jill Wechsler
by Jill Wechsler A new FDA commissioner will have to oversee agency consolidation and new initiatives to counter bioterrorism.
Advertisement
Articles in this issue
about 23 years ago
Bioinformatics Databases ? Questions of Copyrightabout 23 years ago
European Editor's Report ? An Industry Comes of Ageabout 23 years ago
Guest Editorial: Back to the Beginningabout 23 years ago
You Have Failed . . . A Case Study in Warning Letter Remediationabout 23 years ago
Survival Guide to FDA Inspections: Part 3, Responding to ObservationsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Launch in Lockstep: Biopharma Readiness for the CNPV’s Accelerated Clock
2
CDC’s Policy Shift on Autism and Vaccines Spurs Biopharma Quality/System Concerns
3
How Programmable Biology Could Reshape Biologic Drug Development
4
BioPharm Weekly News Roundup—Week of Nov. 17, 2025
5
